Enhancing Patients’ Access to Genomic Diagnostics

A Proposal for Reform of the French Healthcare System to Allow Broader Adoption of Genomic Testing

Genomic profiling, using Genomic Diagnostics, has been defined as “a laboratory method that is used to learn about the genes in a person or in a specific cell type, and the way those genes interact with each other and with the environment.”

Genomic Diagnostics can fundamentally transform healthcare for three main reasons: significantly increasing the breadth, depth and accuracy of the analysis of human health and disease for each patient profiled, bringing more accurate and actionable diagnostic information earlier in the course of disease, and significant economic and societal value through a growing global industry which will positively impact lives of patients around the globe.

To examine the issue of patients’ access to Genomic Diagnostics, Alira Health and EUCOPE have collaborated to create a position paper, addressed to all stakeholders in the French healthcare system: physicians, payers, providers (including hospitals and labs), procurement teams, policy makers, and, of course, patients and their advocates. Continue reading to get the overview of the recommendations that will enhance the Genomic Diagnostics ecosystem in France.

Blog
Published on:
February 15, 2023
If these systemic barriers can be overcome, the French Genomic Diagnostics ecosystem would be fundamentally reformed, improving health outcomes and lowering total healthcare system costs.
The Challenge Presented by Systemic Barriers

While France is a pioneer in ground-breaking genomic innovation, the country has systemic barriers that limit patient access to Genomic Diagnostics. These barriers include early funding programs becoming a bottleneck for innovation, inadequate reimbursement to enable a shift from research use to routine clinical practice, and a general lack of consideration for the patient perspective on Genomic Diagnostics and genomics.

Due to these barriers, access to genomic testing is limited, and the result is nothing less than sub-optimal outcomes for patients. The French healthcare system is also overlooking potential cost-savings due to inefficient care provision across the entire patient pathway. If these systemic barriers can be overcome, the French Genomic Diagnostics ecosystem would be fundamentally reformed, improving health outcomes and lowering total healthcare system costs.

Key Recommendations

To enable this shift, Alira Health and EUCOPE have conducted a robust research process, resulting in these three key recommendations to enhance the Genomic Diagnostics ecosystem in France:

  1. Modify existing early access pathways to enable faster and appropriate reimbursement of promising innovative Genomic Diagnostics, with a clear evidence-based evaluation pathway to determine long term reimbursement.
  2. Facilitate the integration of Genomic Diagnostics into clinical practice by establishing real-world evidence for diagnostics in the context of reimbursement.
  3. Increase the weighting of the patients’ perspective on the value of Genomic Diagnostics in the evaluation process for the reimbursement of Genomic Diagnostics

We encourage all stakeholders in the Genomic Diagnostics ecosystem in France to urgently review and implement the recommendations set forth in this position paper. Patient outcomes will improve, total costs will be minimized, and the French healthcare ecosystem will benefit from the integration and utilization of these tests.

Related news

News November 6, 2023
Alira Health Partners with the Patient Empowerment Network Enabling Cancer Patients to Take Control of their Health and Treatment
Alira Health and the Patient Empowerment Network announced their partnership in supporting those impacted by cancer with a mobile platform delivering essential support for their medical needs.
Oncology Patient Advocacy Patient Engagement
Multimedia November 2, 2023
How to Increase Patient Engagement in Your Clinical Trials
Join this webinar hosted by France Biotech to learn best practices and how to overcome challenges in engaging patients in your clinical trial.
Biotech France Patient Engagement
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Multimedia September 25, 2023
How to Co-Design Your Solution With Patients
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
Patient Engagement
Blog August 28, 2023
Mandatory Patient-Focused Listening Sessions with CMS: What Manufacturers Need to Know
To learn about patient-focused listening sessions, their potential impact, and how manufacturers can prepare, we spoke with our experts.
Drug Development Patient Advocacy Patient Engagement
Case Studies July 11, 2023
Mid-size Pharma Accelerates Early Clinical Trial Engagement of Patients with A Rare Neurological Disease
A mid-size pharma company sought an experienced advisor who could help them engage patients for an open-label extension clinical study in a rare neurological disease.
Clinical Trials Patient Engagement Pharma Rare Disease
News June 29, 2023
Alira Health Partners with LACNETS and the Carcinoid Cancer Foundation to Help NET Cancer Patients Take Control of Their Healthcare Journey
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announced today the addition of the Learn Advocate Connect Neuroendocrine(...)
Patient Advocacy Patient Centricity Patient Engagement Press Release
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.